Companies › Iovance Biotherapeutics
5 active drug programs in 11 registered trials: 6 Phase 1, 5 Phase 2; Oncology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Lifileucel Tumor-infiltrating lymphocytes (TIL) autologous cell therapy | – | Phase 2 | Melanoma (Skin Cancer); Endometrial Cancer; Sarcoma; Locally Advanced Melanoma … | Dec 2027 |
| LN-145 Autologous tumor infiltrating lymphocytes (TIL) expanded ex vivo, administered after lymph | – | Phase 2 | Metastatic Non Small Cell Lung Cancer; Cutaneous Squamous Cell Carcinoma | Dec 2030 |
| IOV-4001 Autologous tumor infiltrating lymphocyte (TIL) therapy | – | Phase 1 | Unresectable Melanoma | Sep 2027 |
| IOV-3001 Modified interleukin-2 fusion protein | IL2 | Phase 1 | Unresectable Melanoma | Jun 2032 |
| LN-145/LN-144 Autologous tumor-infiltrating lymphocytes (TIL) therapy | – | Phase 1 | Soft Tissue Sarcoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06566092 | LN-145/LN-144 | Phase 1 | Soft Tissue Sarcoma | Oncology | Jun 2026 |
| NCT05176470 | Lifileucel | Phase 1 | Locally Advanced Melanoma | Oncology | Dec 2026 |
| NCT05607095 | Lifileucel | Phase 1 | Uveal Melanoma | Oncology | May 2027 |
| NCT05361174 | IOV-4001 | Phase 1 | Unresectable Melanoma | Oncology | Sep 2027 |
| NCT05640193 | Lifileucel | Phase 1 | Metastatic Melanoma | Oncology | Nov 2027 |
| NCT07288203 | Lifileucel | Phase 2 | Melanoma (Skin Cancer) | Oncology | Dec 2027 |
| NCT06481592 | Lifileucel | Phase 2 | Endometrial Cancer | Oncology | May 2028 |
| NCT07288073 | LN-145 | Phase 2 | Cutaneous Squamous Cell Carcinoma | Oncology | Sep 2028 |
| NCT04614103 | LN-145 | Phase 2 | Metastatic Non Small Cell Lung Cancer | Oncology | Dec 2030 |
| NCT06940739 | IOV-3001 | Phase 1 | Unresectable Melanoma | Oncology | Jun 2032 |
| NCT07741877 | Lifileucel | Phase 2 | Sarcoma | Oncology | Sep 2033 |
Cash and short-term investments of $376m on 2026-09-30; operating cash outflow about $184m a year; runway about 24 months at that burn, to Oct 2028; 3 of 5 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Salspera Shanghai Juncell Therapeutics Grit Biotechnology Binhui Biopharmaceutical Orca Biosystems
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.